Skip to content
    Guidelines & Consensus

    Multidisciplinary Stage III NSCLC Management in the Immunotherapy Era

    Gallina et alJTO clinical and research reports

    Multidisciplinary Stage III NSCLC Management in the Immunotherapy Era
    A multisocietal Italian Delphi consensus involving experts from AIOM, SICT, SIAPEC, and AIRO addressed clinical uncertainties in the multimodal management of stage III non-small cell lung cancer (NSCLC) in the immunotherapy era. Across two Delphi rounds evaluating 65 statements with a 9-point Likert scale, the multidisciplinary panel achieved consensus on 62 statements spanning baseline evaluation, local therapies, and integrated systemic approaches.
    The panel reached strong agreement on comprehensive baseline staging protocols, which include contrast-enhanced computed tomography (CT), positron emission tomography (PET), brain magnetic resonance imaging (MRI), and systematic mediastinal staging utilizing endosonographic techniques. In addition, molecular characterization—specifically evaluating Programmed Death-Ligand 1 (PD-L1) expression alongside testing for EGFR and ALK alterations—was deemed essential for informing treatment selection.
    For treatment pathways, neoadjuvant chemo-immunotherapy was endorsed as the preferred strategy for most patients presenting with resectable stage III disease without actionable oncogenic drivers. When surgery is undertaken, lung-sparing resections were strongly favored, with pneumonectomy reserved for highly selected cases. For patients with unresectable stage III NSCLC, the consensus affirmed that concurrent chemoradiotherapy followed by consolidation immunotherapy remains the standard of care.

    Key Takeaways

    • Consensus was reached on 62 of 65 statements, endorsing neoadjuvant chemo-immunotherapy as the preferred approach for most patients with resectable stage III NSCLC lacking actionable driver alterations.
    • For unresectable stage III disease, concurrent chemoradiotherapy followed by consolidation immunotherapy remains the standard of care, while lung-sparing surgical resections were favored over pneumonectomy for resectable cases.
    Read the original sourceJTO clinical and research reports